Biotech will continue to outperform, with innovation supported by drug pricing pressure

The biotechnology sector is expected to continue to outperform and generate returns for investors, said Carl Harald Janson, lead manager at SV Life Sciences Managers at the recently held annual general meeting of the International Biotechnology Trust (IBT).

Shareholders showed very strong support by voting positively for all resolutions including the continuation vote which passed with 99.99% of votes in favor, which reaffirmed faith in the Manager’s ability to deliver value following a period of strong performance.

Mr Janson said: “The outlook for the sector continues to be strong. Biotech companies continue to impress with their scientific breakthroughs and execution.”